Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tianjin Sets Up Pharmaceutical Innovation And Technology Transfer Center

This article was originally published in PharmAsia News

Executive Summary

Tianjin Institute of Pharmaceutical Research (TIPR), Tianjin Centre for Drug Safety Evaluation and Research, and TIPR Pharmaceutical Responsible Co. Ltd. will jointly set up a pharmaceutical innovation and technology transfer center at the Binhai Hi-Tech Park in Tianjin. The 370-million-yuan ($51.5 million) facility is expected to generate up to 1.5 billion yuan ($208.9 million) of production value for its programs within three years of operation. The center will raise Tianjing city's drug R&D and technical service levels by stimulating beneficial interaction between scientific research and industry. The integration of innovation and technology transfer will greatly spur the development of bioengineering and pharmaceutical industries in the area. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067692

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel